Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib plus Camrelizumab in previously treated advanced HCC
NCT07238881Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dalpiciclib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Objective Response Rate at 6 months. Started Nov 2025; status: recruiting.
02
Drugs
dalpiciclib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07238881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07238881.